HK Stock MarketDetailed Quotes

02196 FOSUN PHARMA

Watchlist
  • 12.640
  • +0.320+2.60%
Not Open May 2 16:08 CST
33.78BMarket Cap15.16P/E (TTM)

FOSUN PHARMA Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
(FY)Dec 31, 2021
Turnover
-6.56%10.16B
-5.85%41.25B
-2.92%30.7B
0.16%21.32B
4.68%10.87B
12.73%43.81B
16.91%31.62B
26.10%21.28B
28.91%10.38B
28.85%38.86B
Operating income
-6.56%10.16B
-5.85%41.25B
-2.92%30.7B
0.16%21.32B
4.68%10.87B
12.73%43.81B
16.91%31.62B
26.10%21.28B
28.91%10.38B
28.85%38.86B
Cost of sales
----
6.80%-21.6B
----
7.60%-10.7B
----
-14.53%-23.17B
----
-40.23%-11.58B
----
-47.30%-20.23B
Operating expenses
4.10%-5.08B
6.80%-21.6B
6.70%-15.78B
7.60%-10.7B
9.67%-5.29B
-14.53%-23.17B
-24.03%-16.91B
-40.23%-11.58B
-50.91%-5.86B
-47.30%-20.23B
Gross profit
-8.90%5.08B
-4.79%19.65B
1.43%14.92B
9.41%10.62B
23.28%5.58B
10.77%20.64B
9.68%14.71B
12.56%9.7B
8.42%4.52B
13.42%18.63B
Selling expenses
10.93%-2.24B
-5.90%-9.71B
-11.23%-7.23B
-21.46%-5.07B
-21.59%-2.52B
-0.77%-9.17B
0.94%-6.5B
0.86%-4.18B
0.51%-2.07B
-11.51%-9.1B
Administrative expenses
-1.13%-1B
-14.80%-4.5B
-20.61%-3.17B
-22.11%-2.1B
-25.25%-991.09M
-18.15%-3.92B
-16.73%-2.63B
-14.44%-1.72B
-17.46%-791.31M
-9.16%-3.31B
Research and development expenses
14.38%-829.57M
-1.02%-4.35B
-10.22%-3.16B
-16.81%-2.13B
-19.66%-968.87M
-12.11%-4.3B
-18.60%-2.86B
-16.98%-1.83B
-26.35%-809.68M
-37.27%-3.84B
Profit from asset sales
185.51%434.1K
----
-95.50%6.3M
----
-173.65%-507.68K
----
2,026.44%140.1M
----
-120.77%-185.52K
----
Revaluation surplus
86.36%-20.14M
----
141.76%806.34M
----
89.13%-147.61M
----
-245.96%-1.93B
----
-2,628.67%-1.36B
----
-Changes in the fair value of other assets
86.36%-20.14M
----
141.76%806.34M
----
89.13%-147.61M
----
-245.96%-1.93B
----
-2,628.67%-1.36B
----
Impairment and provision
58.87%-10.53M
-101.82%-131.93M
-189.88%-372.49M
-153.61%-57.98M
-328.87%-25.6M
11.68%-65.37M
51.81%-128.49M
-54.42%-22.86M
21.40%-5.97M
29.40%-74.02M
-Other impairment is provision
58.87%-10.53M
-101.82%-131.93M
-189.88%-372.49M
-153.61%-57.98M
-328.87%-25.6M
11.68%-65.37M
51.81%-128.49M
-54.42%-22.86M
21.40%-5.97M
29.40%-74.02M
Operating interest expense
----
----
----
-37.47%-603.38M
----
----
----
---438.91M
----
6.63%-822.54M
Special items of operating profit
-49.69%416.77M
353.64%1.09B
-24.67%2.49B
2,266.92%992.21M
-46.80%828.41M
-91.36%239.26M
62.78%3.3B
-97.11%41.92M
199.90%1.56B
68.10%2.77B
Operating profit
-22.91%1.3B
-40.08%2.05B
4.02%4.1B
5.12%1.64B
70.06%1.69B
-19.44%3.43B
-22.64%3.94B
-43.83%1.56B
-22.91%992.85M
37.32%4.25B
Financing income
----
28.66%363.65M
----
----
----
--282.64M
----
----
----
----
Financing cost
-7.26%-280.22M
-37.46%-1.32B
-99.46%-756.08M
----
-144.12%-261.26M
---963.81M
3.66%-379.07M
----
16.70%-107.02M
----
Share of profits of associates
----
15.36%2.39B
----
24.43%1.12B
----
1.60%2.07B
----
-2.92%898.58M
----
18.85%2.04B
Share of profit from joint venture company
----
13.63%-202.03M
----
3.74%-95.84M
----
5.44%-233.93M
----
-6.13%-99.56M
----
-85.65%-247.39M
Special items of earning before tax
93.06%-2.94M
----
73.78%-49.74M
----
-410.57%-42.38M
----
-474.73%-189.71M
----
41.92%-8.3M
----
Earning before tax
-26.46%1.02B
-28.46%3.28B
-2.33%3.29B
12.85%2.66B
57.80%1.38B
-24.20%4.58B
-27.76%3.37B
-28.62%2.36B
-23.37%877.53M
29.18%6.04B
Tax
14.16%-232.2M
41.06%-369.5M
-4.43%-638.65M
-19.87%-610.25M
-11.16%-270.51M
41.21%-626.92M
16.37%-611.54M
7.55%-509.09M
-46.15%-243.36M
-44.53%-1.07B
After-tax profit from continuing operations
-29.44%786.22M
-26.46%2.91B
-3.83%2.65B
10.92%2.05B
75.70%1.11B
-20.55%3.95B
-29.87%2.76B
-32.84%1.85B
-35.20%634.16M
26.30%4.98B
Earning after tax
-29.44%786.22M
-26.46%2.91B
-3.83%2.65B
10.92%2.05B
75.70%1.11B
-20.55%3.95B
-29.87%2.76B
-32.84%1.85B
-35.20%634.16M
26.30%4.98B
Minority profit
38.66%176.49M
134.84%508.8M
14.66%370.74M
-12.93%267.75M
-28.33%127.28M
-12.48%216.66M
-12.66%323.34M
13.38%307.51M
35.08%177.59M
-10.68%247.56M
Profit attributable to shareholders
-38.22%609.73M
-35.81%2.4B
-6.29%2.28B
15.68%1.78B
116.17%986.97M
-20.97%3.74B
-31.66%2.44B
-37.89%1.54B
-46.11%456.57M
29.10%4.73B
Basic earnings per share
-37.84%0.23
-37.06%0.9
-8.51%0.86
11.67%0.67
105.56%0.37
-22.70%1.43
-32.37%0.94
-38.14%0.6
-45.45%0.18
29.37%1.85
Diluted earnings per share
-37.84%0.23
-37.06%0.9
-9.57%0.85
11.67%0.67
105.56%0.37
-22.70%1.43
-32.37%0.94
-38.14%0.6
-45.45%0.18
29.37%1.85
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
Audit Opinions
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
Auditor
--
Ernst & Young (Special General Partnership)
--
--
--
Ernst & Young (Special General Partnership)
--
--
--
Ernst & Young (Special General Partnership)
(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022(FY)Dec 31, 2021
Turnover -6.56%10.16B-5.85%41.25B-2.92%30.7B0.16%21.32B4.68%10.87B12.73%43.81B16.91%31.62B26.10%21.28B28.91%10.38B28.85%38.86B
Operating income -6.56%10.16B-5.85%41.25B-2.92%30.7B0.16%21.32B4.68%10.87B12.73%43.81B16.91%31.62B26.10%21.28B28.91%10.38B28.85%38.86B
Cost of sales ----6.80%-21.6B----7.60%-10.7B-----14.53%-23.17B-----40.23%-11.58B-----47.30%-20.23B
Operating expenses 4.10%-5.08B6.80%-21.6B6.70%-15.78B7.60%-10.7B9.67%-5.29B-14.53%-23.17B-24.03%-16.91B-40.23%-11.58B-50.91%-5.86B-47.30%-20.23B
Gross profit -8.90%5.08B-4.79%19.65B1.43%14.92B9.41%10.62B23.28%5.58B10.77%20.64B9.68%14.71B12.56%9.7B8.42%4.52B13.42%18.63B
Selling expenses 10.93%-2.24B-5.90%-9.71B-11.23%-7.23B-21.46%-5.07B-21.59%-2.52B-0.77%-9.17B0.94%-6.5B0.86%-4.18B0.51%-2.07B-11.51%-9.1B
Administrative expenses -1.13%-1B-14.80%-4.5B-20.61%-3.17B-22.11%-2.1B-25.25%-991.09M-18.15%-3.92B-16.73%-2.63B-14.44%-1.72B-17.46%-791.31M-9.16%-3.31B
Research and development expenses 14.38%-829.57M-1.02%-4.35B-10.22%-3.16B-16.81%-2.13B-19.66%-968.87M-12.11%-4.3B-18.60%-2.86B-16.98%-1.83B-26.35%-809.68M-37.27%-3.84B
Profit from asset sales 185.51%434.1K-----95.50%6.3M-----173.65%-507.68K----2,026.44%140.1M-----120.77%-185.52K----
Revaluation surplus 86.36%-20.14M----141.76%806.34M----89.13%-147.61M-----245.96%-1.93B-----2,628.67%-1.36B----
-Changes in the fair value of other assets 86.36%-20.14M----141.76%806.34M----89.13%-147.61M-----245.96%-1.93B-----2,628.67%-1.36B----
Impairment and provision 58.87%-10.53M-101.82%-131.93M-189.88%-372.49M-153.61%-57.98M-328.87%-25.6M11.68%-65.37M51.81%-128.49M-54.42%-22.86M21.40%-5.97M29.40%-74.02M
-Other impairment is provision 58.87%-10.53M-101.82%-131.93M-189.88%-372.49M-153.61%-57.98M-328.87%-25.6M11.68%-65.37M51.81%-128.49M-54.42%-22.86M21.40%-5.97M29.40%-74.02M
Operating interest expense -------------37.47%-603.38M---------------438.91M----6.63%-822.54M
Special items of operating profit -49.69%416.77M353.64%1.09B-24.67%2.49B2,266.92%992.21M-46.80%828.41M-91.36%239.26M62.78%3.3B-97.11%41.92M199.90%1.56B68.10%2.77B
Operating profit -22.91%1.3B-40.08%2.05B4.02%4.1B5.12%1.64B70.06%1.69B-19.44%3.43B-22.64%3.94B-43.83%1.56B-22.91%992.85M37.32%4.25B
Financing income ----28.66%363.65M--------------282.64M----------------
Financing cost -7.26%-280.22M-37.46%-1.32B-99.46%-756.08M-----144.12%-261.26M---963.81M3.66%-379.07M----16.70%-107.02M----
Share of profits of associates ----15.36%2.39B----24.43%1.12B----1.60%2.07B-----2.92%898.58M----18.85%2.04B
Share of profit from joint venture company ----13.63%-202.03M----3.74%-95.84M----5.44%-233.93M-----6.13%-99.56M-----85.65%-247.39M
Special items of earning before tax 93.06%-2.94M----73.78%-49.74M-----410.57%-42.38M-----474.73%-189.71M----41.92%-8.3M----
Earning before tax -26.46%1.02B-28.46%3.28B-2.33%3.29B12.85%2.66B57.80%1.38B-24.20%4.58B-27.76%3.37B-28.62%2.36B-23.37%877.53M29.18%6.04B
Tax 14.16%-232.2M41.06%-369.5M-4.43%-638.65M-19.87%-610.25M-11.16%-270.51M41.21%-626.92M16.37%-611.54M7.55%-509.09M-46.15%-243.36M-44.53%-1.07B
After-tax profit from continuing operations -29.44%786.22M-26.46%2.91B-3.83%2.65B10.92%2.05B75.70%1.11B-20.55%3.95B-29.87%2.76B-32.84%1.85B-35.20%634.16M26.30%4.98B
Earning after tax -29.44%786.22M-26.46%2.91B-3.83%2.65B10.92%2.05B75.70%1.11B-20.55%3.95B-29.87%2.76B-32.84%1.85B-35.20%634.16M26.30%4.98B
Minority profit 38.66%176.49M134.84%508.8M14.66%370.74M-12.93%267.75M-28.33%127.28M-12.48%216.66M-12.66%323.34M13.38%307.51M35.08%177.59M-10.68%247.56M
Profit attributable to shareholders -38.22%609.73M-35.81%2.4B-6.29%2.28B15.68%1.78B116.17%986.97M-20.97%3.74B-31.66%2.44B-37.89%1.54B-46.11%456.57M29.10%4.73B
Basic earnings per share -37.84%0.23-37.06%0.9-8.51%0.8611.67%0.67105.56%0.37-22.70%1.43-32.37%0.94-38.14%0.6-45.45%0.1829.37%1.85
Diluted earnings per share -37.84%0.23-37.06%0.9-9.57%0.8511.67%0.67105.56%0.37-22.70%1.43-32.37%0.94-38.14%0.6-45.45%0.1829.37%1.85
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKAS
Audit Opinions --Unqualified Opinion------Unqualified Opinion------Unqualified Opinion
Auditor --Ernst & Young (Special General Partnership)------Ernst & Young (Special General Partnership)------Ernst & Young (Special General Partnership)

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg